Evidence map›Paper›PMID 39194655›Full record

ArticleJournal of functional biomaterials2024

In Vitro Biocompatibility Assessment of Bioengineered PLA-Hydrogel Core-Shell Scaffolds with Mesenchymal Stromal Cells for Bone Regeneration.

Federica Re, Luciana Sartore, Chiara Pasini, Matteo Ferroni, Elisa Borsani, Stefano Pandini, Andrea Bianchetti, Camillo Almici, Lorena Giugno, Roberto Bresciani and 5 more

Abstract read
In one paragraph

Article in Journal of functional biomaterials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Feature Papers in Bone Biomaterials.Journal of functional biomaterials · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Federica ReUnit of Blood Diseases and Cell Therapies, Department of Clinical and Experimental Sciences, University of Brescia, "ASST-Spedali Civili" Hospital of Brescia, 25123 Brescia, Italy.ORCID 0000-0003-4219-8695
Luciana SartoreUniversity Center of Research "STem cells, bioENgineering and regenerative MEDicine"-STENMED, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0003-0268-6467
Chiara PasiniUniversity Center of Research "STem cells, bioENgineering and regenerative MEDicine"-STENMED, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0001-7478-239X
Matteo FerroniUniversity Center of Research "STem cells, bioENgineering and regenerative MEDicine"-STENMED, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-4231-9162
Elisa BorsaniUniversity Center of Research "STem cells, bioENgineering and regenerative MEDicine"-STENMED, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-9746-0876
Stefano PandiniUniversity Center of Research "STem cells, bioENgineering and regenerative MEDicine"-STENMED, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0003-2390-8495
Andrea BianchettiUniversity Center of Research "STem cells, bioENgineering and regenerative MEDicine"-STENMED, University of Brescia, 25123 Brescia, Italy.
Camillo AlmiciUniversity Center of Research "STem cells, bioENgineering and regenerative MEDicine"-STENMED, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-9438-2569
Lorena GiugnoDivision of Anatomy and Physiopathology, Department of Clinical and Experimental Sciences, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0003-1937-2499
Roberto BrescianiDepartment of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-7881-7550
Silvia MuttiUnit of Blood Diseases and Cell Therapies, Department of Clinical and Experimental Sciences, University of Brescia, "ASST-Spedali Civili" Hospital of Brescia, 25123 Brescia, Italy.ORCID 0009-0007-2859-4145
Federica TrentaUnit of Blood Diseases and Cell Therapies, Department of Clinical and Experimental Sciences, University of Brescia, "ASST-Spedali Civili" Hospital of Brescia, 25123 Brescia, Italy.ORCID 0009-0001-8986-458X
Simona BernardiUnit of Blood Diseases and Cell Therapies, Department of Clinical and Experimental Sciences, University of Brescia, "ASST-Spedali Civili" Hospital of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-3494-2624
Mirko FarinaUnit of Blood Diseases and Cell Therapies, Department of Clinical and Experimental Sciences, University of Brescia, "ASST-Spedali Civili" Hospital of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-2980-9028
Domenico RussoUnit of Blood Diseases and Cell Therapies, Department of Clinical and Experimental Sciences, University of Brescia, "ASST-Spedali Civili" Hospital of Brescia, 25123 Brescia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human mesenchymal stromal cells (hMSCs), whether used alone or together with three-dimensional scaffolds, are the best-studied postnatal stem cells in regenerative medicine. In this study, innovative composite scaffolds consisting of a core-shell architecture were seeded with bone-marrow-derived hMSCs (BM-hMSCs) and tested for their biocompatibility and remarkable capacity to promote and support bone regeneration and mineralization. The scaffolds were prepared by grafting three different amounts of gelatin-chitosan (CH) hydrogel into a 3D-printed polylactic acid (PLA) core (PLA-CH), and the mechanical and degradation properties were analyzed. The BM-hMSCs were cultured in the scaffolds with the presence of growth medium (GM) or osteogenic medium (OM) with differentiation stimuli in combination with fetal bovine serum (FBS) or human platelet lysate (hPL). The primary objective was to determine the viability, proliferation, morphology, and spreading capacity of BM-hMSCs within the scaffolds, thereby confirming their biocompatibility. Secondly, the BM-hMSCs were shown to differentiate into osteoblasts and to facilitate scaffold mineralization. This was evinced by a positive Von Kossa result, the modulation of differentiation markers (osteocalcin and osteopontin), an expression of a marker of extracellular matrix remodeling (bone morphogenetic protein-2), and collagen I. The results of the energy-dispersive X-ray analysis (EDS) clearly demonstrate the presence of calcium and phosphorus in the samples that were incubated in OM, in the presence of FBS and hPL, but not in GM. The chemical distribution maps of calcium and phosphorus indicate that these elements are co-localized in the same areas of the sections, demonstrating the formation of hydroxyapatite. In conclusion, our findings show that the combination of BM-hMSCs and PLA-CH, regardless of the amount of hydrogel content, in the presence of differentiation stimuli, can provide a construct with enhanced osteogenicity for clinically relevant bone regeneration.

Indexed as

3D printingbone regenerationgelatin–chitosan hydrogelhuman mesenchymal stromal cellshuman platelet lysatePLAscaffold designtissue engineering

Identifiers

PMID39194655
PMCPMC11355418

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.